A5072469819- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Bladder and Urothelial Cancer Treatments
- Ferroptosis and cancer prognosis
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Lymphoma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Cutaneous lymphoproliferative disorders research
- Cancer Risks and Factors
- Prostate Cancer Treatment and Research
- Thyroid Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Urinary and Genital Oncology Studies
- Peptidase Inhibition and Analysis
- Multiple and Secondary Primary Cancers
- Radiopharmaceutical Chemistry and Applications
- Inflammatory Biomarkers in Disease Prognosis
- Cancer, Stress, Anesthesia, and Immune Response
- Head and Neck Cancer Studies
Fondazione IRCCS Istituto Nazionale dei Tumori
2020-2024
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
2024
University of Milan
2021-2023
Politecnico di Milano
2022
IFOM
2021
University of Salerno
2016
(1) Background: In advanced non-small cell lung cancer (aNSCLC), programmed death ligand 1 (PD-L1) remains the only biomarker for candidate patients to immunotherapy (IO). This study aimed at using artificial intelligence (AI) and machine learning (ML) tools improve response efficacy predictions in aNSCLC treated with IO. (2) Methods: Real world data blood microRNA signature classifier (MSC) were used. Patients divided into responders (R) non-responders (NR) determine if overall survival of...
Introduction Artificial Intelligence (AI) methods are being increasingly investigated as a means to generate predictive models applicable in the clinical practice. In this study, we developed model predict efficacy of immunotherapy (IO) patients with advanced non-small cell lung cancer (NSCLC) using eXplainable AI (XAI) Machine Learning (ML) methods. Methods We prospectively collected real-world data from an NSCLC condition receiving immune-checkpoint inhibitors (ICIs) either single agent or...
4578 Background: Combining multitargeted receptor tyrosine kinase inhibitor (TKI) with checkpoint inhibitors has shown synergistic effect in pts UC due to the immunomodulatory propriety of VEGFR inhibitors. We investigated if combination CABO and DURVA advanced non-UC histology (VHs) a phase II study (NCT03824691). Herein preliminary results interim analysis. Methods: Patients affected by VHs recurred or progressed after failure at least one line platinum-based chemotherapy for metastatic...
To evaluate and compare the DNA yield quality extracted from lymph node fine needle cytology (FNC) samples stored on FTA cards to those cryopreserved, assess immunoglobulin heavy light chains (IGHK) T-Cell receptor beta gamma (TCRBG) PCR tests.DNA extractions were performed FNC of 80 non-Hodgkin lymphomas (NHL), four myelomas 56 benign reactive hyperplasias (BRH) cryopreserved cards. The JAK2 gene was amplified integrity IGHK/TCRBG clonality status tested.IGHK monoclonality found in 99%...
Among the several next-generation tyrosine kinase inhibitors (TKIs) tested against uncommon EFGR alterations, poziotinib has been demonstrated to be a powerful agent for metastatic non-small-cell lung cancer (mNSCLC) with aberrations in HER2 exon 20, and FDA approval is being sought previously-treated population. Poziotinib also shown activity mNSCLC EGFR 20. Herein, we report first published case of patient affected by harbouring an 20 insertion (EGFRex20ins) mutation who achieved complete...
The PEOPLE trial aimed to identify new immune biomarkers in negative and low programmed death-ligand 1 (PD-L1) (0%-49%) advanced non-small-cell lung cancer (aNSCLC) patients treated with first-line pembrolizumab. Here we report the main outcomes circulating analysis.The primary endpoint of this phase II was identification associated progression-free survival (PFS). Overall (OS), objective response rate (ORR), disease control (DCR), duration (DoR) safety were secondary endpoints. Absolute...
High body mass index (BMI) has been associated with worse clinical outcomes in patients early-stage breast cancer (BC), and its negative effects could be mediated by hyperglycemia/diabetes. However, the prognostic impact of high BMI HER2-positive (HER2+) BC remains controversial.We conducted a retrospective study to investigate baseline or glycemia on relapse-free survival (RFS) overall (OS) surgically resected, stage I-III HER2+ treated standard-of-care, trastuzumab-containing adjuvant...
712 Background: Nivolumab, an immune checkpoint inhibitor of PD-1, demonstrated a significant OS benefit in patients with metastatic renal cell carcinoma (mRCC), progression after previous line therapy anti-VEGFR agents. However, the features effective response and predictive biomarkers clinical to PD-1 blockade have not yet been recognized. Methods: I-RENE is prospective translational multicenter Italian study real-life mRCC treated nivolumab or cabozantinib failure 82 were enrolled from...
TPS5115 Background: it is reasonable to offer radiotherapy (RT) improve outcomes for patients with newly diagnosed M1 prostate cancer < 5 bone metastases (HORRAD) or low volume disease (STAMPEDE) (Burdett, S et al., Eur. Urol. 2019). Data from clinical randomized trials evaluating feasibility and overall benefit of cytoreductive radical prostatectomy (cRP) in oligometastatic ormone sensitive are not available. The rationale performing eliminate lethal clones ofcastration-resistant...
Background: Clinical and laboratory biomarkers in patients with advanced non-small-cell lung cancer (aNSCLC) receiving chemo-immunotherapy (CIT) are still poorly explored. Materials & methods: All consecutive aNSCLC who received at least one cycle of first-line CIT were enrolled. The impact several clinical on outcomes was evaluated through Cox proportional hazard models. Results: Higher neutrophil-to-lymphocyte ratio shown to be an independent prognostic biomarker both worse...
687 Background: As components of the liquid biopsy, Extracellular Vesicles (EVs) have gained major interest as biomarkers diagnosis, prognosis and prediction response/resistance to cancer therapies. Here we investigated if plasma EV immune profile, size concentration in concert with proteomics might discriminate responding from non-responding patients affected by advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) undergoing cabozantinib (CABO) plus Durvalumab (DURVA)...
Acute kidney injury (AKI) frequently develops in patients receiving cancer therapy and requires a wide differential diagnosis due to possible role of unique drug-related factors, addition common pre- post-renal causes. Rapid development new molecular targeted anti-cancer drugs immunotherapies has opened unprecedented possibilities treatment at the price an increased spectrum renal side effects.
688 Background: Internationally avelumab is approved as maintenance therapy for patients (pts) with LA/mUC whose disease did not progress after 1L platinum-based chemotherapy. However, 54% of pts progressed on avelumab. Limited data are available predictive biomarker efficacy. Artificial intelligence (AI) methods being increasingly investigated to generate models applicable in clinical practice. In this study, we developed a set machine learning (ML) classifiers and survival analysis...
684 Background: Preliminary results of the interim analysis ARCADIA trial have shown that combining multitargeted receptor tyrosine kinase inhibitor CABO with checkpoint DURVA has promising activity and a manageable safety profile in patients (pts) affected by UC recurred or progressed after failure at least one line platinum-based chemotherapy for metastatic disease phase II study (NCT03824691). To identify peripheral blood biomarkers potentially associated clinical response, we carried out...